Catalent

Traded on the St. Petersburg Stock Exchange
Catalent, Inc. is a global provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products.
Catalent stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Catalent balance sheet

Report period2019 2020 2021 20222023 Q2 24
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Catalent cash flows

Report period2019 2020 2021 20222023 Q2 24 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Catalent multipliers

Report period2019 2020 2021 20222023 Q2 24 TTM
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
Net Debt/EBITDA adj.
EV/EBITDA
EV/EBITDA adj.

Catalent profitability

Report period2019 2020 2021 20222023 Q2 24 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Catalent assets
Catalent cash flows

Catalent shares

TickerNameTypeNominal valueISINPrice
CTLT:USCatalent, Inc.Common share-US1488061029$55.48
Catalent news
03.05.2022
Catalent's GAAP net income for 9 months of fiscal year 2022 was $331 million, down 17.9% from $403 million in the prior year. Revenue increased 25.1% to $3.515 billion from $2.81 billion a year earlier.
01.02.2022
Catalent's GAAP net income for 6 months of fiscal year 2022 was $190 million, up 11.1% from $171 million in the prior year. Revenue increased 27.6% to $2.242 billion from $1.757 billion a year earlier.
02.11.2021
Net income of Catalent under GAAP for the three months of fiscal year 2022 was $93 million, up 13.4% compared to $82 million in the previous year. Revenue increased 21.2% to $1.025 billion from $0.846 billion a year earlier.
30.08.2021
Catalent is acquiring Bettera Holdings for $1 billion. The company produces nutritional supplements in the form of chewing gum, soft chewy candies and lozenges. The deal is expected to close by the end of 2021.
General information
Company nameCatalent
Tags#s&p500 index
SectorHealth Care / Health Care Equipment & Services / Health Care Providers & Services / Health Care Services
Business address14 SCHOOLHOUSE ROAD SOMERSET NJ 08873 (732) 537-6200
Mailing address14 SCHOOLHOUSE ROAD SOMERSET NJ 08873
Websitewww.catalent.com
Information disclosurewww.sec.gov